Gilead Sciences, Inc.

1368 articles with Gilead Sciences, Inc.

• 

  Movers and Shakers for Sept. 4

  9/4/2018

  Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
• 

  Updated: Merck Scores FDA Approval for Two New HIV Treatments

  8/31/2018

  Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
• 

  Amgen’s Laura Hamill Jumps to Gilead as Executive VP

  8/29/2018

  Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.

• Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations

  8/28/2018

  Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead’s senior leadership team.

• 

  U.K.’s NICE Rejects Gilead Sciences’ Yescarta Over the Drug’s Cost

  8/28/2018

  The United Kingdom’s government-funded health service isn’t being so nice to Gilead Science’s CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for the agency to justify.

• Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy

  8/27/2018

  New Option for Adult Patients in Europe as Axicabtagene Ciloleucel Becomes the First CAR T to Receive European Approval for Two Types of Aggressive Non-Hodgkin Lymphoma

• 

  Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling Hi...

  8/23/2018

  Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events.
• 

  Does CAR-T Therapy Have a Payment Problem?

  8/23/2018

  By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and n...

• Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences

  8/22/2018

  More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients

• 

  Sierra Oncology Acquires Gilead’s Momelotinib in $198 Million Deal

  8/22/2018

  Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
• 

  Biotech Movers and Shakers Aug 20

  8/20/2018

  This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Science’s new(ish) chief medical officer was leaving the company six months after taking over the position.
• 

  Taking a Look at Trends in Biotherapeutics

  8/15/2018

  It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
• 

  J&J Reports Positive Phase III Data for its Two-Drug HIV Combo

  8/15/2018

  Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.
• 

  Gilead CMO Departs, Company Reorganizes Leadership

  8/15/2018

  Foster City, Calif.-based Gilead Sciences reorganized some of its executive leadership team after it was announced that Chief Medical Officer Andrew Cheng is leaving the company to pursue other opportunities.

• Gilead Sciences Announces Executive Promotions

  8/14/2018

  Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients.

• AHF Files Petition for Review of Gilead AIDS Drug Patent Case with U.S. Supreme Court

  8/13/2018

  In January 2016, AHF filed a federal lawsuit against Gilead Sciences, Inc. and two other defendants alleging drug patent manipulation and anti-trust claims regarding slightly different formulations of tenofovir, a key HIV/AIDS drug found in Gilead’s all-in-one Fixed Dose Combination HIV/AIDS treatments.

• China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection

  8/6/2018

  Genvoya is the First TAF-Based Regimen Approved in China for Adults and Adolescents with HIV

• Louisiana HIV Patients file Federal Personal Injury Cases Against Gilead Over Key HIV Drug

  7/27/2018

  Legal actions filed by two patients with HIV from Louisiana targets Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir disoproxil fumarate (“TDF”).

• 

  Gilead Boss to Step Down at the End of the Year

  7/26/2018

  Gilead Sciences’ president and chief executive officer, John Milligan, is retiring after 28 years with the company. Gilead is beginning a search for a replacement.

• Gilead Sciences Announces CEO John F. Milligan to Step Down

  7/25/2018

  Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as President and Chief Executive Officer.